Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2399-3642
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells ; volume:5 ; number:1 ; day:11 ; month:11 ; year:2022 ; pages:1-13 ; date:12.2022
Communications biology ; 5, Heft 1 (11.11.2022), 1-13, 12.2022
- Urheber
-
Schanin, Julia
Korver, Wouter
Brock, Emily C.
Leung, John
Benet, Zachary
Luu, Thuy
Chang, Katherine
Xu, Alan
Freitas, Naomi De
Luehrsen, Kenneth
Brehm, Michael A.
Wong, Alan
Youngblood, Bradford A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-022-04207-w
- URN
-
urn:nbn:de:101:1-2023012522003303267606
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schanin, Julia
- Korver, Wouter
- Brock, Emily C.
- Leung, John
- Benet, Zachary
- Luu, Thuy
- Chang, Katherine
- Xu, Alan
- Freitas, Naomi De
- Luehrsen, Kenneth
- Brehm, Michael A.
- Wong, Alan
- Youngblood, Bradford A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model
An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model
An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody
Sialic acid/Siglec axis regulates antibody-mediated neutrophil cytotoxicity towards cancer cells
ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
Section VIII: Agonistic
Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery
Regulation of the effective anti-tumor CD4+ T cell immunity by agonistic CD137 antibody
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
Die Rolle von Siglec-H und Siglec-15 in Infektionen und Autoimmunität
Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates
Contribution of SIGLEC-11 and SIGLEC-16 receptors to neuro-inflammation and neurodegeneration
Fluorescence lifetime imaging ophthalmoscope and supplement of agonistic TrkB antibody in a glaucoma model